Key result
Administrative data for identifying chemotherapy side effects is not always suitable for populating economic models due to inherent data limitations, despite its easy access and generalizability.
Why the study?
Can administrative data be used to accurately measure chemotherapy side effects compared to patient self-reports?
Cohort
Can administrative data be used to accurately measure chemotherapy side effects compared to patient self-reports?
Administrative data has limitations when used to identify chemotherapy side effects for economic models compared to patient self-reports.
Answers are grounded in this paper and cite their sources.
Cautions against relying solely on administrative claims for cardio-oncology cost-effectiveness modeling.
Many of the issues with using data from clinical trials and observational studies for economic evaluations are highlighted in the case of chemotherapy side effects. We present the results of an observational cohort study using linked administrative data. The chemotherapy side effects identified in the administrative data are compared with patient self-reports of such events. The results of these comparisons are then used to guide a discussion of the issues surrounding the use of administrative data to identify clinical events for the population of economic models. Although the advantages of easy access and generalizability of the results make administrative data an attractive option for populating economic models, this is not always possible because of the limitations of these data.
No takes yet. Share an insight, caveat, or question.
Pearce et al. (2014) conducted a cohort in Chemotherapy side effects. Administrative data vs. Patient self-reports was evaluated on Chemotherapy side effects. Administrative data for identifying chemotherapy side effects is not always suitable for populating economic models due to inherent data limitations, despite its easy access and generalizability.
Synapse has enriched 10 related papers. Consider them for comparative context: